title: A phase II study of leucovorin, 5-FU and docetaxel combination chemotherapy in patients with inoperable or postoperative relapsed gastric cancer.
abstract: OBJECTIVE
  To estimate the effect and toxicity of bimonthly low-dose leucovorin (LV) and fluorouracil (5-FU) bolus plus continuous infusion(LV5FU2) with docetaxel combination chemotherapy in patients with inoperable or postoperative relapsed gastric cancer.
  
  
  METHODS
  Total 27 patients are enrolled in this study. LV 20 mg/m(2) (bolus), 5FU 400 mg/m(2) (bolus), 5-FU 600 mg/m(2) (24-hour continuous infusion) on day 1, 2, 15, and 16, docetaxel 60 mg/m(2) (1-hour infusion) on day 15 every 4 weeks.
  
  
  RESULTS
  Total of 141 cycles were administered and response rate were 36.8% with 2 complete response (10.5%) and 5 partial response (26.3%) in 19 evaluable patients. The median response duration is 8.1 months (95% CI, 4.0 approximately 12.1). The median progression-free survival time is 6.7 months (95% CI, 5.0 approximately 8.5) and the median overall survival time is 11.9 months (95% CI, 4.8 approximately 19.1). The grade 3-4 toxicity of neutropenia (24.8%) and anemia (11.3%), neutropenic fever (2.8%) is observed. The grade 1 toxicity of injection site reaction is observed all patients and the grade 1-2 toxicity of alopecia is observed 60%.
  
  
  CONCLUSIONS
  LV5FU2 with docetaxel combination chemotherapy is effective and tolerable in patients with inoperable or postoperative relapsed gastric cancer.
authors.affiliation: Department of Internal Medicine, Chung-Ang University College of Medicine, Seoul, Korea.
authors.forename: Kwang-Sun
authors.initials: KS
authors.lastname: Lee
authors.forename: Ha-Yeon
authors.initials: HY
authors.lastname: Lee
authors.forename: Eun-Kyung
authors.initials: EK
authors.lastname: Park
authors.forename: Joung-Soon
authors.initials: JS
authors.lastname: Jang
authors.forename: Sang-Jae
authors.initials: SJ
authors.lastname: Lee
references.citation: Cancer. 1978 Mar;41(3):941-7
references.pmid: 638980
references.citation: J Clin Oncol. 1996 Aug;14(8):2274-9
references.pmid: 8708717
references.citation: Br J Surg. 2001 Feb;88(2):278-85
references.pmid: 11167881
references.citation: J Natl Cancer Inst. 1993 Dec 1;85(23):1937-44
references.pmid: 8230285
references.citation: Cancer Res Treat. 2004 Apr;36(2):103-14
references.pmid: 20396549
references.citation: J Clin Oncol. 2004 Nov 1;22(21):4319-28
references.pmid: 15514373
references.citation: J Natl Cancer Inst. 2000 Feb 2;92(3):205-16
references.pmid: 10655437
references.citation: J Clin Oncol. 2005 Aug 20;23(24):5660-7
references.pmid: 16110025
references.citation: Ann Oncol. 2001 Jan;12(1):47-51
references.pmid: 11249048
references.citation: J Clin Oncol. 1989 Oct;7(10):1407-18
references.pmid: 2476530
references.citation: J Clin Oncol. 2006 Jun 20;24(18):2903-9
references.pmid: 16782930
references.citation: J Clin Oncol. 1998 Jan;16(1):301-8
references.pmid: 9440757
references.citation: J Clin Oncol. 1997 Jan;15(1):368-81
references.pmid: 8996164
references.citation: Br J Cancer. 1994 Aug;70(2):380-3
references.pmid: 7914428
references.citation: Med Oncol. 1996 Jun;13(2):87-93
references.pmid: 9013471
references.citation: J Clin Oncol. 2001 Apr 15;19(8):2282-92
references.pmid: 11304782
references.citation: Ann Oncol. 2005;16 Suppl 1:i22-3
references.pmid: 15888740
references.citation: J Clin Oncol. 2001 Nov 1;19(21):4097-106
references.pmid: 11689577
references.citation: J Clin Oncol. 2006 Nov 1;24(31):4991-7
references.pmid: 17075117
references.citation: J Clin Oncol. 1997 Feb;15(2):808-15
references.pmid: 9053508